Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients: Is it necessary?

Clinical Pharmacokinetics

Volumn 41, Issue 5, 2002, Pages 319-327

  Mourad, M ^a   Wallemacq, P ^a   Konig J ^a   De Frahan, E H ^a   Eddour, D C ^a   De Meyer, M ^a   Malaise, J ^a   Squifflet, J P ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; PATIENT MONITORING; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SIDE EFFECT;

EID: 0036299291     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241050-00001     Document Type: Review

References (63)

1. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection
2. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
3. Mycophenolate mofetil for the prevention of acute rejection in cadaveric renal allograft recipients
4. The design and the development of an immunosuppressive drug, mycophenolate mofetil
5. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy
6. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation
7. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients: RS-61443 Investigation Committee-Japan
8. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation
9. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: Implications for therapeutic drug monitoring
10. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil
11. Pharmacokinetic basis of efficient and safe use of low mycophenolate mofetil (MMF, 1g/day) in combination with tacrolimus in kidney transplant patients
12. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression
13. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration
14. Clinical pharmacokinetics of mycophenolate mofetil
15. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil
16. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil
17. Manual and automated (robotic) high-performance liquid chromatography methods for the determination of mycophenolic acid and its glucuronide conjugate in human plasma
18. Analytical performance of an EMIT® assay for mycophenolic acid plasma
19. Analytical and clinical evaluation of the EMIT mycophenolic acid immunoassay in kidney transplantation
20. Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performed liquid chromatography assay
21. Evaluation of the EMIT mycophenolic acid assay from Dade Behring
22. Mycophenolic acid monitoring: Evaluation of the EMIT MPA immunoassay in kidney and lung transplantation
23. Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite
24. Therapeutic drug monitoring of mycophenolic acid: Comparison of HPLC and immunoassay reveals new MPA metabolites
25. Mycophenolate mofetil in renal allograft recipients
26. Co-administration of tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients
27. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients
28. Mycophenolate mofetil as maintenance immunosuppression in pediatric renal transplantation
29. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients
30. Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children
31. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: A report of the German Study Group on mycophenolate mofetil therapy
32. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection
33. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: A longitudinal study in pediatric patients
34. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function
35. The effect of renal insufficiency on mycophenolic acid protein binding
36. Pharmacokinetics of mycophenolic acid in renal insufficiency
37. Mycophenolic acid area under the curve values in African, American and Caucasian renal transplant patients are comparable
38. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: Importance of mycophenolic acid therapeutic drug monitoring
39. Mycophenolic acid concentrations are associated with cardiac allograft rejection
40. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection
41. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart rejection study group
42. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients
43. Mycophenolic acid binding to human serum albumin: Characterization and relation to pharmacodynamics
44. Similarities and differences in the glucuronidation of estradiol and estrone by UDP-glucuronosyltransferase in liver microsomes from male and female rats
45. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patient receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings
46. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation
47. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: A cross-sectional study
48. Effect of cyclosporine on mycophenolic acid through levels in kidney transplant recipients
49. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid
50. Assay method for monitoring the inhibitory effects of antimetabolites on the activity of inosinate dehydrogenase in intact human CEM lymphocytes
51. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity
52. Assessment of mycophenolic acid-reduced immunosuppression: A new approach
53. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients
54. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil
55. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil
56. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and emit
57. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: A link to side effects?
58. Absorption profiling of cyclosporine therapy for de novo kidney transplantation: A prospective, randomized study comparing sparse sampling to trough monitoring
59. Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients
60. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients
61. Limited sampling strategy for mycophenolic acid area under the curve
62. Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the plasma concentration-time curve in adult renal transplant patients